FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322752875> ?p ?o ?g. }

• W4322752875 endingPage "226" @default.
• W4322752875 startingPage "215" @default.
• W4322752875 abstract "Introduction. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus (severe acute respiratory syndrome-related coronavirus 2). COVID-19 is now expected to stay with us for many years as a recurring disease. Molnupiravir and favipiravir are oral antiviral drugs with anti-RNA polymerase activity. The Russian Health Ministry has approved molnupiravir and favipiravir for the treatment of COVID-19. The study describes development and validation of high-performance liquid chromatography – tandem mass spectrometry (HPLC-MS/MS) method for the simultaneous determination of β-D-N4-Hydroxycytidine and favipiravir in human blood plasma. The method could be applied in pharmacokinetic study of molnupiravir and favipiravir. Aim. The aim of this study is to develop and validate a HPLC-MS/MS bioanalytical method for the determination of β-D-N4-Hydroxycytidine and favipiravir in human plasma. Materials and methods. The determination of β-D-N4-Hydroxycytidine and favipiravir in human plasma by HPLC-MS/MS. The samples were processed by 0.1 % formic acid in acetonitrile. Internal standard: promethazine. Mobile phase: 0.01 mol/L Ammonium formate buffer solution (Eluent A), 0.1 % formic acid and 0.08 % aqueous ammonia in water/acetonitrile 10 : 90 (Eluent B). Column: Shim-pack GWS C18, 150 × 4.6 mm, 5 μm. Analytical range: 50.00–10000.00 ng/mL for β-D-N4-Hydroxycytidine, 250.00–20000.00 ng/mL for favipiravir in human plasma. Ionization source: electrospray ionization. Detection conditions: 260.00 m/z → 82.10 m/z, 260.00 m/z → 111.00 m/z, 260.00 m/z → 127.95 m/z (β-D-N4-Hydroxycytidine); 156.15 m/z → 65.95 m/z, 156.15 m/z → 85.00 m/z, 156.15 m/z → 113.10 m/z (favipiravir); 285.05 m/z → 198.05 m/z (promethazine). Results and discussion. This method was validated by selectivity, suitability of reference standard, matrix effect, calibration curve, accuracy, precision, spike recovery, the lower limit of quantification, carry-over effect and stability. Conclusion. The HPLC-MS/MS method for quantitative determination of β-D-N4-Hydroxycytidine and favipiravir in human plasma was developed and validated. The analytical range was 50.00–10000.00 ng/mL for β-D-N4-Hydroxycytidine, 250.00–20000.00 ng/mL for favipiravir in human plasma. This method was applied to investigate the pharmacokinetics of molnupiravir and favipiravir." @default.
• W4322752875 created "2023-03-03" @default.
• W4322752875 creator A5002478098 @default.
• W4322752875 creator A5019143656 @default.
• W4322752875 creator A5027235797 @default.
• W4322752875 creator A5036342136 @default.
• W4322752875 creator A5059402346 @default.
• W4322752875 creator A5066900329 @default.
• W4322752875 creator A5075225779 @default.
• W4322752875 creator A5077165923 @default.
• W4322752875 date "2023-02-28" @default.
• W4322752875 modified "2023-10-04" @default.
• W4322752875 title "Simultaneous Determination of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) and Favipiravir in Human Plasma by HPLC-MS/MS" @default.
• W4322752875 cites W3132800081 @default.
• W4322752875 cites W3152320732 @default.
• W4322752875 cites W3163488943 @default.
• W4322752875 cites W3176881508 @default.
• W4322752875 cites W3198019853 @default.
• W4322752875 cites W3198844580 @default.
• W4322752875 cites W3209183617 @default.
• W4322752875 cites W3212389527 @default.
• W4322752875 cites W4200093468 @default.
• W4322752875 cites W4200119590 @default.
• W4322752875 cites W4200354655 @default.
• W4322752875 cites W4200543103 @default.
• W4322752875 cites W4223575774 @default.
• W4322752875 cites W4284671117 @default.
• W4322752875 cites W4294681241 @default.
• W4322752875 cites W4317932889 @default.
• W4322752875 cites W4318065436 @default.
• W4322752875 doi "https://doi.org/10.33380/2305-2066-2023-12-1-215-226" @default.
• W4322752875 hasPublicationYear "2023" @default.
• W4322752875 type Work @default.
• W4322752875 citedByCount "1" @default.
• W4322752875 countsByYear W43227528752023 @default.
• W4322752875 crossrefType "journal-article" @default.
• W4322752875 hasAuthorship W4322752875A5002478098 @default.
• W4322752875 hasAuthorship W4322752875A5019143656 @default.
• W4322752875 hasAuthorship W4322752875A5027235797 @default.
• W4322752875 hasAuthorship W4322752875A5036342136 @default.
• W4322752875 hasAuthorship W4322752875A5059402346 @default.
• W4322752875 hasAuthorship W4322752875A5066900329 @default.
• W4322752875 hasAuthorship W4322752875A5075225779 @default.
• W4322752875 hasAuthorship W4322752875A5077165923 @default.
• W4322752875 hasBestOaLocation W43227528751 @default.
• W4322752875 hasConcept C142724271 @default.
• W4322752875 hasConcept C162356407 @default.
• W4322752875 hasConcept C179998833 @default.
• W4322752875 hasConcept C185592680 @default.
• W4322752875 hasConcept C2775986502 @default.
• W4322752875 hasConcept C2777379063 @default.
• W4322752875 hasConcept C2779134260 @default.
• W4322752875 hasConcept C2779772310 @default.
• W4322752875 hasConcept C3008058167 @default.
• W4322752875 hasConcept C31827203 @default.
• W4322752875 hasConcept C40684141 @default.
• W4322752875 hasConcept C43617362 @default.
• W4322752875 hasConcept C524204448 @default.
• W4322752875 hasConcept C71043704 @default.
• W4322752875 hasConcept C71924100 @default.
• W4322752875 hasConceptScore W4322752875C142724271 @default.
• W4322752875 hasConceptScore W4322752875C162356407 @default.
• W4322752875 hasConceptScore W4322752875C179998833 @default.
• W4322752875 hasConceptScore W4322752875C185592680 @default.
• W4322752875 hasConceptScore W4322752875C2775986502 @default.
• W4322752875 hasConceptScore W4322752875C2777379063 @default.
• W4322752875 hasConceptScore W4322752875C2779134260 @default.
• W4322752875 hasConceptScore W4322752875C2779772310 @default.
• W4322752875 hasConceptScore W4322752875C3008058167 @default.
• W4322752875 hasConceptScore W4322752875C31827203 @default.
• W4322752875 hasConceptScore W4322752875C40684141 @default.
• W4322752875 hasConceptScore W4322752875C43617362 @default.
• W4322752875 hasConceptScore W4322752875C524204448 @default.
• W4322752875 hasConceptScore W4322752875C71043704 @default.
• W4322752875 hasConceptScore W4322752875C71924100 @default.
• W4322752875 hasIssue "1" @default.
• W4322752875 hasLocation W43227528751 @default.
• W4322752875 hasOpenAccess W4322752875 @default.
• W4322752875 hasPrimaryLocation W43227528751 @default.
• W4322752875 hasRelatedWork W1277187992 @default.
• W4322752875 hasRelatedWork W1558772439 @default.
• W4322752875 hasRelatedWork W1992561179 @default.
• W4322752875 hasRelatedWork W2079130042 @default.
• W4322752875 hasRelatedWork W2148112117 @default.
• W4322752875 hasRelatedWork W2351302509 @default.
• W4322752875 hasRelatedWork W2513471305 @default.
• W4322752875 hasRelatedWork W2791978427 @default.
• W4322752875 hasRelatedWork W3194462057 @default.
• W4322752875 hasRelatedWork W4238213830 @default.
• W4322752875 hasVolume "12" @default.
• W4322752875 isParatext "false" @default.
• W4322752875 isRetracted "false" @default.
• W4322752875 workType "article" @default.